Table 3.
Adjusted HRs for receipt of first sick note by follow-up period postindex date
| Comparison and follow-up period postindex date | Sick note rate per 100 person-months (95% CI) | Adjusted HR* (95% CI) | |
| COVID-19 cohort | General population† | ||
| 2020 COVID-19 cohort vs 2019 general population | |||
| 0–30 days | 9.35 (9.24 to 9.46) | 1.99 (1.98 to 2.01) | 4.68 (4.61 to 4.75) |
| 0–90 days | 6.20 (6.14 to 6.27) | 1.48 (1.47 to 1.48) | 3.63 (3.58 to 3.68) |
| 0–150 days | 5.39 (5.33 to 5.45) | 1.31 (1.30 to 1.32) | 3.36 (3.32 to 3.40) |
| Entire follow-up period | 4.88 (4.83 to 4.93) | 1.21 (1.20 to 1.22) | 3.19 (3.15 to 3.23) |
| 2020 COVID-19 cohort vs 2020 general population | |||
| 0–30 days | 9.35 (9.24 to 9.46) | 1.57 (1.55 to 1.58) | 5.94 (5.85 to 6.03) |
| 0–90 days | 6.20 (6.14 to 6.27) | 1.12 (1.11 to 1.13) | 4.67 (4.61 to 4.73) |
| 0–150 days | 5.39 (5.33 to 5.45) | 0.99 (0.99 to 1.00) | 4.32 (4.27 to 4.38) |
| Entire follow-up period | 4.88 (4.83 to 4.93) | 0.93 (0.93 to 0.93) | 4.07 (4.02 to 4.12) |
| 2021 COVID-19 cohort vs 2019 general population | |||
| 0–30 days | 6.51 (6.46 to 6.56) | 1.99 (1.98 to 2.01) | 3.34 (3.30 to 3.38) |
| 0–90 days | 3.50 (3.48 to 3.52) | 1.48 (1.47 to 1.48) | 2.38 (2.35 to 2.41) |
| 0–150 days | 2.91 (2.90 to 2.93) | 1.31 (1.30 to 1.32) | 2.15 (2.13 to 2.17) |
| Entire follow-up period | 2.66 (2.64 to 2.67) | 1.21 (1.20 to 1.22) | 2.02 (2.00 to 2.04) |
| 2021 COVID-19 cohort vs 2021 general population | |||
| 0–30 days | 6.51 (6.46 to 6.56) | 1.97 (1.96 to 1.99) | 3.37 (3.33 to 3.40) |
| 0–90 days | 3.50 (3.48 to 3.52) | 1.47 (1.46 to 1.48) | 2.35 (2.33 to 2.37) |
| 0–150 days | 2.91 (2.90 to 2.93) | 1.32 (1.31 to 1.33) | 2.12 (2.10 to 2.13) |
| Entire follow-up period | 2.66 (2.64 to 2.67) | 1.23 (1.22 to 1.23) | 1.99 (1.98 to 2.01) |
| 2022 COVID-19 cohort vs 2019 general population | |||
| 0–30 days | 4.87 (4.83 to 4.91) | 1.99 (1.98 to 2.01) | 2.27 (2.24 to 2.30) |
| 0–90 days | 2.57 (2.55 to 2.58) | 1.48 (1.47 to 1.48) | 1.73 (1.72 to 1.75) |
| 0–150 days | 2.05 (2.04 to 2.06) | 1.31 (1.30 to 1.32) | 1.63 (1.61 to 1.64) |
| Entire follow-up period | 1.73 (1.72 to 1.73) | 1.21 (1.20 to 1.22) | 1.55 (1.54 to 1.57) |
| 2022 COVID-19 cohort vs 2022 general population | |||
| 0–30 days | 4.87 (4.83 to 4.91) | 2.09 (2.07 to 2.10) | 2.37 (2.34 to 2.39) |
| 0–90 days | 2.57 (2.55 to 2.58) | 1.53 (1.52 to 1.54) | 1.73 (1.73 to 1.76) |
| 0–150 days | 2.05 (2.04 to 2.06) | 1.34 (1.39 to 1.35) | 1.64 (1.62 to 1.65) |
| Entire follow-up period | 1.73 (1.72 to 1.73) | 1.23 (1.22 to 1.23) | 1.57 (1.56 to 1.58) |
Entire follow-up period was up to 10 months. Crude and age-sex-adjusted HRs presented in online supplemental table 6.
*Fully adjusted models include age, sex, IMD quintile, region, ethnicity, obesity, smoking status, hypertension, diabetes, chronic respiratory disease, asthma, chronic cardiac disease, lung cancer, haematological cancer, other cancer, chronic liver disease, other neurological disease, organ transplant, asplenia, HIV, permanent immunodeficiency and rheumatoid arthritis/systemic lupus erythematosus/psoriasis.
†General population age, sex and STP frequency matched with COVID-19 cohort.
IMD, index of multiple deprivation; STP, sustainability and transformation partnership.